Generalized pustular psoriasis treated with apremilast in a patient with multiple medical comorbidities

[1]  J.J. Wu,et al.  Apremilast for a psoriasis patient with HIV and hepatitis C , 2017, Journal of the European Academy of Dermatology and Venereology : JEADV.

[2]  L. Atzmony,et al.  Risk for hepatitis B and C virus reactivation in patients with psoriasis on biologic therapies: A retrospective cohort study and systematic review of the literature , 2017, Journal of the American Academy of Dermatology.

[3]  S. Langan,et al.  Psoriasis and comorbid diseases: Implications for management. , 2017, Journal of the American Academy of Dermatology.

[4]  R. Vangipuram,et al.  Apremilast for the management of moderate to severe plaque psoriasis , 2017, Expert review of clinical pharmacology.

[5]  S. Chimenti,et al.  Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). , 2015, Journal of the American Academy of Dermatology.

[6]  W. Liao,et al.  Biologic therapy in erythrodermic and pustular psoriasis. , 2014, Journal of drugs in dermatology : JDD.

[7]  M. Lebwohl,et al.  Treatment of pustular psoriasis: from the Medical Board of the National Psoriasis Foundation. , 2012, Journal of the American Academy of Dermatology.

[8]  A. Gottlieb,et al.  Treatment of psoriasis in patients with hepatitis C: from the Medical Board of the National Psoriasis Foundation. , 2009, Journal of the American Academy of Dermatology.